Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Neuropharmacology
  4. Volume 23, Issue 7
  5. Article
Volume 23, Issue 7
  • ISSN: 1570-159X
  • E-ISSN: 1875-6190
file format pdf download PDF
file format text download EPUB
side by side viewer icon HTML

Abstract

Objectives

The treatment of Burning Mouth Syndrome (BMS) represents a challenge in tailoring appropriate medication for individual patients. The augmentation of pregabalin to conventional treatment has shown promising outcomes in relieving pain and improving the quality of life in chronic pain conditions. This study aimed to compare the efficacy of vortioxetine with other antidepressants (SSRIs/SNRIs) in combination with pregabalin in a cohort of unresponsive BMS patients and to predict treatment response by using clinical data.

Methods

A 52-week randomized, open-label, comparative clinical study was conducted, enrolling 203 BMS patients previously treated with one antidepressant for 12 weeks and non-responders to the treatment (clinical trial registration: NCT06025474). The study sample included two groups: Group A (136) received vortioxetine, while Group B (67) received SSRIs/SNRIs. Pregabalin (75 mg/day) was added to both groups, with a potential dosage increase to 150 mg/day for inadequate responders after 12 weeks. Treatment response was assessed with VAS and SF-MPQ, HAM-A, and HAM-D scores at 12, 24, 36, and 52 weeks. Stepwise logistic regression analysis was used to predict treatment response.

Results

A total of 84 (61.8%) BMS patients in Group A and 39 (58.2%) in Group B showed treatment response. Group A reported a faster onset of action compared to Group B (44.8% 22.4% at time 1; :0.002**) and lower adverse event rates (8.8% 20.8%; :0.001).

Conclusion

The addition of pregabalin to vortioxetine may be considered a potential treatment option for BMS. Further research is required to corroborate these findings and optimize personalized treatment approaches for BMS patients.

Clinical Trial Registration Number

ClinicalTrials.gov (NCT06025474).

© 2025 The Author(s). Published by Bentham Science Publishers.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/cn/10.2174/1570159X22999240729103717
2024-07-29
2025-05-18

  • From This Site

    /content/journals/cn/10.2174/1570159X22999240729103717
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cn/23/7/CN-23-7-06.html?itemId=/content/journals/cn/10.2174/1570159X22999240729103717&mimeType=html&fmt=ahah

References

  1. TanH.L. RentonT. Burning mouth syndrome: An update.Cephalalgia Rep.20203251581632097014310.1177/2515816320970143
     [Google Scholar]
  2. WuS. ZhangW. YanJ. NomaN. YoungA. YanZ. Worldwide prevalence estimates of burning mouth syndrome: A systematic review and meta‐analysis.Oral Dis.20222861431144010.1111/odi.13868 33818878
     [Google Scholar]
  3. AdamoD. CalabriaE. CanforaF. CoppolaN. PecoraroG. D’AnielloL. Burning mouth syndrome: Analysis of diagnostic delay in 500 patients.Oral Dis.202430315431554 36825392
     [Google Scholar]
  4. HamonB. OrliaguetM. MiseryL. BoisraméS. Burning mouth syndrome and pelvodynia: A literature review.Medicine20231023e3264810.1097/MD.0000000000032648 36701734
     [Google Scholar]
  5. AdamoD. SpagnuoloG. Burning mouth syndrome: An overview and future perspectives.Int. J. Environ. Res. Public Health202220168210.3390/ijerph20010682 36613002
     [Google Scholar]
  6. ChoiJ.H. KimM.J. KhoH.S. Oral health‐related quality of life and associated factors in patients with burning mouth syndrome.J. Oral Rehabil.202148215015910.1111/joor.13110 33031643
     [Google Scholar]
  7. AdamoD. PecoraroG. FortunaG. AmatoM. MarenziG. AriaM. MignognaM.D. Assessment of oral health-related quality of life, measured by OHIP-14 and GOHAI, and psychological profiling in burning mouth syndrome: A case‐control clinical study.J. Oral Rehabil.2020471425210.1111/joor.12864 31332814
     [Google Scholar]
  8. CanforaF. CalabriaE. PecoraroG. D AnielloL. AriaM. MarenziG. SammartinoP. MignognaM.D. AdamoD. The use of self-report questionnaires in an analysis of the multidimensional aspects of pain and a correlation with the psychological profile and quality of life in patients with burning mouth syndrome: A case-control study.J. Oral Rehabil.202249989091410.1111/joor.13343 35611463
     [Google Scholar]
  9. CanforaF. CalabriaE. CuocoloR. UggaL. BuonoG. MarenziG. GasparroR. PecoraroG. AriaM. D’AnielloL. MignognaM.D. AdamoD. Burning fog: Cognitive impairment in burning mouth syndrome.Front. Aging Neurosci.20211372741710.3389/fnagi.2021.727417 34475821
     [Google Scholar]
  10. AdamoD. SardellaA. VaroniE. LajoloC. BiasottoM. OttavianiG. VescoviP. SimonazziT. PenteneroM. ArdoreM. SpadariF. BombeccariG. MontebugnoliL. GissiD.B. CampisiG. PanzarellaV. CarboneM. ValpredaL. GiulianiM. AriaM. Lo MuzioL. MignognaM.D. The association between burning mouth syndrome and sleep disturbance: A case–control multicentre study.Oral Dis.201824463864910.1111/odi.12807 29156085
     [Google Scholar]
  11. SchiavoneV. AdamoD. VentrellaG. MorlinoM. De NotarisE.B. RavelM.G. KusmannF. PiantadosiM. PollioA. FortunaG. MignognaM.D. Anxiety, depression, and pain in burning mouth syndrome: first chicken or egg?Headache20125261019102510.1111/j.1526‑4610.2012.02171.x 22607629
     [Google Scholar]
  12. KimJ.Y. KimY.S. KoI. KimD.K. Association between burning mouth syndrome and the development of depression, anxiety, dementia, and parkinson disease.JAMA Otolaryngol. Head Neck Surg.2020146656156910.1001/jamaoto.2020.0526 32352482
     [Google Scholar]
  13. AdamoD. PecoraroG. AriaM. FaviaG. MignognaM.D. Vortioxetine in the treatment of mood disorders associated with burning mouth syndrome: Results of an open-label, flexible-dose pilot study.Pain Med.201911010.1093/pm/pnz120 31343684
     [Google Scholar]
  14. MaltaC.E.N. CostaF.W.G. DiasC.C. CarlosA.C.A.M. SousaF.B. SilvaP.G.B. TeófiloC.R. Association of anxiety, depression, and stress with burning mouth syndrome: A case-control study.Gen. Dent.20216944652 34185668
     [Google Scholar]
  15. TuT.T.H. MiuraA. ShinoharaY. MikuzukiL. KawasakiK. SugawaraS. SugaT. WatanabeT. WatanabeM. UmezakiY. YoshikawaT. MotomuraH. TakenoshitaM. ToyofukuA. Evaluating burning mouth syndrome as a comorbidity of atypical odontalgia: The impact on pain experiences.Pain Pract.201818558058610.1111/papr.12647 28972293
     [Google Scholar]
  16. Blackburn-MunroG. Blackburn-MunroR.E. Chronic pain, chronic stress and depression: Coincidence or consequence?J. Neuroendocrinol.200113121009102310.1046/j.0007‑1331.2001.00727.x 11722697
     [Google Scholar]
  17. ChouR. HuffmanL.H. Nonpharmacologic therapies for acute and chronic low back pain: A review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline.Ann. Intern. Med.2007147749250410.7326/0003‑4819‑147‑7‑200710020‑00007 17909210
     [Google Scholar]
  18. GalliF. LodiG. SardellaA. VegniE. Role of psychological factors in burning mouth syndrome: A systematic review and meta-analysis.Cephalalgia201737326527710.1177/0333102416646769 27121358
     [Google Scholar]
  19. TanH.L. SmithJ.G. HoffmannJ. RentonT. A systematic review of treatment for patients with burning mouth syndrome.Cephalalgia202242212816110.1177/03331024211036152 34404247
     [Google Scholar]
  20. AdamoD. PecoraroG. CoppolaN. CalabriaE. AriaM. MignognaM. Vortioxetine versus other antidepressants in the treatment of burning mouth syndrome: An open‐label randomized trial.Oral Dis.20212741022104110.1111/odi.13602 32790904
     [Google Scholar]
  21. DoldM. KasperS. Evidence-based pharmacotherapy of treatment-resistant unipolar depression.Int. J. Psychiatry Clin. Pract.2017211132310.1080/13651501.2016.1248852 27848269
     [Google Scholar]
  22. KeksN. HopeJ. KeoghS. Switching and stopping antidepressants.Aust. Prescr.20163937683 27346915
     [Google Scholar]
  23. DoldM. BartovaL. FuggerG. MitschekM.M.M. FabbriC. SerrettiA. MendlewiczJ. SoueryD. ZoharJ. MontgomeryS. KasperS. Pregabalin augmentation of antidepressants in major depression - results from a European multicenter study.J. Affect. Disord.202229648549210.1016/j.jad.2021.09.063 34653701
     [Google Scholar]
  24. KaraiskosD. PappaD. TzavellasE. SiarkosK. KatirtzoglouE. PapadimitriouG.N. PolitisA. Pregabalin augmentation of antidepressants in older patients with comorbid depression and generalized anxiety disorder-an open‐label study.Int. J. Geriatr. Psychiatry201328110010510.1002/gps.3800 22431439
     [Google Scholar]
  25. KurianB.T. GreerT.L. TrivediM.H. Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms.Expert Rev. Neurother.20099797598410.1586/ern.09.53 19589048
     [Google Scholar]
  26. ZarebaG. New treatment options in the management of fibromyalgia: Role of pregabalin.Neuropsychiatr. Dis. Treat.2008461193120110.2147/NDT.S3257 19337459
     [Google Scholar]
  27. CalandreE. Morillas-ArquesP. Rodriguez-LopezC. Rico-VillademorosF. HidalgoJ. Pregabalin augmentation of quetiapine therapy in the treatment of fibromyalgia: An open-label, prospective trial.Pharmacopsychiatry2007402687110.1055/s‑2007‑972572 17447176
     [Google Scholar]
  28. ZahlanG. De Clifford-FaugèreG. Nguena NguefackH.L. GuénetteL. PagéM.G. BlaisL. LacasseA. Polypharmacy and excessive polypharmacy among persons living with chronic pain: A cross-sectional study on the prevalence and associated factors.J. Pain Res.2023163085310010.2147/JPR.S411451 37719270
     [Google Scholar]
  29. ZambelliZ. HalsteadE.J. IlesR. FidalgoA.R. DimitriouD. The 2021 NICE guidelines for assessment and management of chronic pain: A cross-sectional study mapping against a sample of 1,000* in the community.Br. J. Pain202216443944910.1177/20494637221083837 36032346
     [Google Scholar]
  30. DerryS. BellR.F. StraubeS. WiffenP.J. AldingtonD. MooreR.A. Pregabalin for neuropathic pain in adults.Cochrane Database Syst. Rev.201911CD007076 30673120
     [Google Scholar]
  31. ZaccaraG. GangemiP. PeruccaP. SpecchioL. The adverse event profile of pregabalin: A systematic review and meta‐analysis of randomized controlled trials.Epilepsia201152482683610.1111/j.1528‑1167.2010.02966.x 21320112
     [Google Scholar]
  32. AllenE.N. ChandlerC.I.R. MandimikaN. LeisegangC. BarnesK. Eliciting adverse effects data from participants in clinical trials.Cochrane Libr.201820181MR00003910.1002/14651858.MR000039.pub2 29372930
     [Google Scholar]
  33. PhillipsR. HazellL. SauzetO. CorneliusV. Analysis and reporting of adverse events in randomised controlled trials: A review.BMJ Open201992e02453710.1136/bmjopen‑2018‑024537 30826796
     [Google Scholar]
  34. SchulzK.F. AltmanD.G. MoherD. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials.Trials20101113210.1186/1745‑6215‑11‑32 20334632
     [Google Scholar]
  35. FurukawaT.A. CiprianiA. CowenP.J. LeuchtS. EggerM. SalantiG. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: A systematic review and dose-response meta-analysis.Lancet Psychiatry20196760160910.1016/S2215‑0366(19)30217‑2 31178367
     [Google Scholar]
  36. International Classification of Orofacial Pain, 1st edition (ICOP).Cephalalgia202040212922110.1177/0333102419893823
     [Google Scholar]
  37. HawkerG.A. MianS. KendzerskaT. FrenchM. Measures of adult pain: Visual analog scale for pain (VAS Pain), numeric rating scale for pain (NRS Pain), McGill pain questionnaire (MPQ), Short-form mcgill pain questionnaire (SF-MPQ), chronic pain grade scale (CPGS), short form-36 bodily pain scale (SF-36 BPS), and measure of intermittent and constant osteoarthritis pain (ICOAP).Arthritis Care Res.201163S11)(Suppl. 11S240S25210.1002/acr.20543 22588748
     [Google Scholar]
  38. HamiltonM. Development of a rating scale for primary depressive illness.Br. J. Soc. Clin. Psychol.19676427829610.1111/j.2044‑8260.1967.tb00530.x 6080235
     [Google Scholar]
  39. HamiltonM. The assessment of anxiety states by rating.Br. J. Med. Psychol.1959321505510.1111/j.2044‑8341.1959.tb00467.x 13638508
     [Google Scholar]
  40. MorrissR. LeeseM. ChatwinJ. BaldwinD. Inter-rater reliability of the hamilton depression rating scale as a diagnostic and outcome measure of depression in primary care.J. Affect. Disord.20081112-320421310.1016/j.jad.2008.02.013 18374987
     [Google Scholar]
  41. CurcioG. TempestaD. ScarlataS. MarzanoC. MoroniF. RossiniP.M. FerraraM. De GennaroL. Validity of the italian version of the pittsburgh sleep quality index (PSQI).Neurol. Sci.201334451151910.1007/s10072‑012‑1085‑y 22526760
     [Google Scholar]
  42. KadouriA. CorrubleE. FalissardB. The improved clinical global impression scale (iCGI): Development and validation in depression.BMC Psychiatry200771710.1186/1471‑244X‑7‑7 17284321
     [Google Scholar]
  43. NorburyA. RobbinsT.W. SeymourB. Value generalization in human avoidance learning.eLife20187e3477910.7554/eLife.34779 29735014
     [Google Scholar]
  44. AmirdelfanK. GlinerB.E. KapuralL. SitzmanB.T. VallejoR. YuC. CarawayD. RotteA. Province-AzaldeR. KramesE. A proposed definition of remission from chronic pain, based on retrospective evaluation of 24-month outcomes with spinal cord stimulation.Postgrad. Med.2019131427828610.1080/00325481.2019.1592401 30901266
     [Google Scholar]
  45. de la VegaR. RacineM. CastarlenasE. SoléE. RoyR. JensenM.P. MiróJ. CaneD. The role of sleep quality and fatigue on the benefits of an interdisciplinary treatment for adults with chronic pain.Pain Pract.201919435436210.1111/papr.12746 30447174
     [Google Scholar]
  46. PostemaP. WildeA. The measurement of the QT interval.Curr. Cardiol. Rev.201410328729410.2174/1573403X10666140514103612 24827793
     [Google Scholar]
  47. FaulF. ErdfelderE. LangA.G. BuchnerA. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences.Behav. Res. Methods200739217519110.3758/BF03193146 17695343
     [Google Scholar]
  48. KimH.Y. Statistical notes for clinical researchers: Chi-squared test and Fisher’s exact test.Restor. Dent. Endod201742215215510.5395/rde.2017.42.2.152 28503482
     [Google Scholar]
  49. In LeeK. KovalJ.J. Determination of the best significance level in forward stepwise logistic regression.Commun. Stat. Simul. Comput.199726255957510.1080/03610919708813397
     [Google Scholar]
  50. OlivaresJ.M. ÁlvarezE. CarrascoJ.L. PérezP.M. López-GómezV. Pregabalin for the treatment of patients with generalized anxiety disorder with inadequate treatment response to antidepressants and severe depressive symptoms.Int. Clin. Psychopharmacol.201530526527110.1097/YIC.0000000000000087 26111356
     [Google Scholar]
  51. ShowrakiM. Pregabalin in the treatment of depression.J. Psychopharmacol.200721888388410.1177/0269881107078496 17984164
     [Google Scholar]
  52. Antoun ReyadA. MishrikyR. GirgisE. Pharmacological and non-pharmacological management of burning mouth syndrome: A systematic review.Dent. Med. Probl.202057329530410.17219/dmp/120991 33113291
     [Google Scholar]
  53. GondaX. SharmaS.R. TaraziF.I. Vortioxetine: A novel antidepressant for the treatment of major depressive disorder.Expert Opin. Drug Discov.2019141818910.1080/17460441.2019.1546691 30457395
     [Google Scholar]
  54. Sowa-KućmaM. Pańczyszyn-TrzewikP. MisztakP. JaeschkeR.R. SendekK. StyczeńK. DatkaW. KopernyM. Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant.Pharmacol. Rep.201769459560110.1016/j.pharep.2017.01.030 28499187
     [Google Scholar]
  55. BennabiD. HaffenE. Van WaesV. Vortioxetine for cognitive enhancement in major depression: From animal models to clinical research.Front. Psychiatry20191077110.3389/fpsyt.2019.00771 31780961
     [Google Scholar]
  56. VaianaA.M. ChenY. GelfondJ. Johnson-PaisT.L. LeachR.J. RamamurthyC. ThompsonI.M. MorilakD.A. Effects of vortioxetine on hippocampal-related cognitive impairment induced in rats by androgen deprivation as a model of prostate cancer treatment.Transl. Psychiatry202313130710.1038/s41398‑023‑02600‑5 37788996
     [Google Scholar]
  57. ZuenaA.R. MafteiD. AlemàG.S. Dal MoroF. LattanziR. CasoliniP. NicolettiF. Multimodal antidepressant vortioxetine causes analgesia in a mouse model of chronic neuropathic pain.Mol. Pain201814174480691880898710.1177/1744806918808987 30289053
     [Google Scholar]
  58. TodorovićM. MicovA. NastićK. TomićM. PecikozaU. VukovićM. Stepanović-PetrovićR. Vortioxetine as an analgesic in preclinical inflammatory pain models: Mechanism of action.Fundam. Clin. Pharmacol.202236223724910.1111/fcp.12737 34820899
     [Google Scholar]
  59. Turan YücelN. KandemirÜ. Demir ÖzkayÜ. CanÖ.D. 5-HT1A serotonergic, α-adrenergic and opioidergic receptors mediate the analgesic efficacy of vortioxetine in mice.Molecules20212611324210.3390/molecules26113242 34071269
     [Google Scholar]
  60. AdamoD. PecoraroG. AriaM. FaviaG. MignognaM.D. Vortioxetine in the treatment of mood disorders associated with burning mouth syndrome: Results of an open-label, flexible-dose pilot study.Pain Med.2020211185194 31343684
     [Google Scholar]
  61. FanelliD. WellerG. LiuH. New serotonin-norepinephrine reuptake inhibitors and their anesthetic and analgesic considerations.Neurol. Int.202113449750910.3390/neurolint13040049 34698218
     [Google Scholar]
  62. MarksD. ShahM. PatkarA. MasandP. ParkG.Y. PaeC.U. Serotonin-norepinephrine reuptake inhibitors for pain control: Premise and promise.Curr. Neuropharmacol.20097433133610.2174/157015909790031201 20514212
     [Google Scholar]
  63. RobinsonC. DalalS. ChitneniA. PatilA. BergerA.A. MahmoodS. OrhurhuV. KayeA.D. HasoonJ. A look at commonly utilized serotonin noradrenaline reuptake inhibitors (SNRIs) in chronic pain.Health Psychol. Res.20221023230910.52965/001c.32309 35774919
     [Google Scholar]
  64. StahlS.M. Anticonvulsants as anxiolytics, part 2: Pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels.J. Clin. Psychiatry200465446046110.4088/JCP.v65n0401 15119905
     [Google Scholar]
  65. GajrajN.M. Pregabalin: Its pharmacology and use in pain management.Anesth. Analg.200710561805181510.1213/01.ane.0000287643.13410.5e 18042886
     [Google Scholar]
  66. RussellI.J. CroffordL.J. LeonT. CappelleriJ.C. BushmakinA.G. WhalenE. BarrettJ.A. SadoskyA. The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome.Sleep Med.200910660461010.1016/j.sleep.2009.01.009 19410509
     [Google Scholar]
  67. GenerosoM.B. TrevizolA.P. KasperS. ChoH.J. CordeiroQ. ShiozawaP. Pregabalin for generalized anxiety disorder.Int. Clin. Psychopharmacol.2017321495510.1097/YIC.0000000000000147 27643884
     [Google Scholar]
  68. ItoM. TokuraT. YoshidaK. NagashimaW. KimuraH. UmemuraE. TachibanaM. MiyauchiT. KobayashiY. AraoM. OzakiN. KuritaK. Five patients with burning mouth syndrome in whom an antidepressant (serotonin-noradrenaline reuptake inhibitor) was not effective, but pregabalin markedly relieved pain.Clin. Neuropharmacol.201538415816110.1097/WNF.0000000000000093 26166242
     [Google Scholar]
  69. Bonilla-JaimeH. Sánchez-SalcedoJ.A. Estevez-CabreraM.M. Molina-JiménezT. Cortes-AltamiranoJ.L. Alfaro-RodríguezA. Depression and pain: Use of antidepressants.Curr. Neuropharmacol.202220238440210.2174/1570159X19666210609161447 34151765
     [Google Scholar]
  70. ArnoldL.M. RussellI.J. DiriE.W. DuanW.R. YoungJ.P.Jr SharmaU. MartinS.A. BarrettJ.A. HaigG. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia.J. Pain20089979280510.1016/j.jpain.2008.03.013 18524684
     [Google Scholar]
  71. McIntyreR.S. FloreaI. PedersenM.M. ChristensenM.C. Head-to-head comparison of vortioxetine versus desvenlafaxine in patients with major depressive disorder with partial response to SSRI therapy: Results of the VIVRE study.J Clin Psychiatry202384423m1478010.4088/JCP.23m14780
     [Google Scholar]
  72. OstuzziG. GastaldonC. TettamantiM. CartabiaM. MontiI. AgugliaA. AgugliaE. BartoliF. CallegariC. CanozziA. CarboneE.A. CarràG. CarusoR. CavallottiS. ChiappiniS. ColasanteF. CompriB. D’AgostinoA. De FazioP. de FilippisR. GariM. IelminiM. IngrossoG. MammarellaS. MartinottiG. RodolicoA. RonconeR. SterziE. TarsitaniL. TibertoE. TodiniL. AmaddeoF. D’AvanzoB. AgugliaE. AgugliaA. AlessiM.C. AvincolaG. BachiB. BarbatoA. BarbuiC. BartoliF. BernasconiG. BirgillitoA. BissoE. BonoraS. CalabreseA. CallegariC. CalloviniT. CanestroA. CanonicoS. CapogrossoC.A. CarboneE. CarosielliD. CarràG. CartabiaM. CaselliI. CavaleriD. CavallottiS. CavallottoC. CescaM. ChiarenzaC. CioniR.M. ColocciniS. CruciataM. CumerlatoC. D’AgostinoA. D’AvanzoB. De FazioP. De FilippisR. De PalmaM. Del VecchioS. Della RoccaB. Di NataleC. D’OnofrioE. EspaI. FiorG. GancitanoM. GariM. GastaldonC. GiordanoB. GiustiL. GrassiL. GuzziP. IelminiM. IngrossoG. IsellaC. LaxA. MammarellaS. MaranoL. MarconiF. MarellaM. MetelliA. MichencigG. MiuliA. MoncadaA. MontiI. MorelloP. MorettiF. MorrealeM. MoscaA. NastiC. NoséM. OgheriF. OrestiM. OrnaghiA. OstuzziG. PalpellaD. PancheriC. PapolaD. PasseriS. PettorussoM. PiacentiS. PinucciI. PuglieseV. PurgatoM. RaniaM. RobbiF. RodolicoA. RomitoS. RonchiB. RonconeR. RoselliV. Segura-GarciaC. SignorelliM.S. SimonelliG. SocialiA. SterziE. SturialeS. TambelliA. TettamantiM. TodescoB. TrabuccoA. TurriniG. VillaV. WiedenmannF. ZambutoL. ZaniniE. ZanniniC. ZerbinatiL. BarbatoA. BarbuiC. Tolerability of vortioxetine compared to selective serotonin reuptake inhibitors in older adults with major depressive disorder (VESPA): A randomised, assessor-blinded and statistician-blinded, multicentre, superiority trial.EClinicalMedicine20246910249110.1016/j.eclinm.2024.102491 38384338
     [Google Scholar]
  73. NomikosG.G. TomoriD. ZhongW. AffinitoJ. PaloW. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older.CNS Spectr.201722434836210.1017/S1092852916000626 27869048
     [Google Scholar]
  74. Schulze-BonhageA. Pharmacokinetic and pharmacodynamic profile of pregabalin and its role in the treatment of epilepsy.Expert Opin. Drug Metab. Toxicol.20139110511510.1517/17425255.2013.749239 23205518
     [Google Scholar]
  75. Iborra-EgeaO. AimoA. MartiniN. Galvez-MontonC. BurchielliS. PanichellaG. PassinoC. EmdinM. Bayes-GenisA. The potential anti-remodeling effect of paroxetine after myocardial infarction may be blunted by beta-blockers.Front. Cardiovasc. Med.2022988724810.3389/fcvm.2022.887248 35898267
     [Google Scholar]
  76. NagamineT. WatanabeT. The catastrophic perception of pain in burning mouth syndrome may be associated with sympathetic tone as indicated by the qtc interval.Innov. Clin. Neurosci.2024211-389 38495607
     [Google Scholar]
  77. LiC. LiuS. LuX. TaoF. Role of descending dopaminergic pathways in pain modulation.Curr. Neuropharmacol.201917121176118210.2174/1570159X17666190430102531 31182003
     [Google Scholar]
  78. OliveiraP. RibeiroJ. DonatoH. MadeiraN. Smoking and antidepressants pharmacokinetics: A systematic review.Ann. Gen. Psychiatry20171611710.1186/s12991‑017‑0140‑8 28286537
     [Google Scholar]
  79. ZhangW. LinH. ZouM. YuanQ. HuangZ. PanX. ZhangW. Nicotine in inflammatory diseases: Anti-inflammatory and pro-inflammatory effects.Front. Immunol.20221382688910.3389/fimmu.2022.826889 35251010
     [Google Scholar]
  80. MagwaiT. XuluK.R. Physiological genomics plays a crucial role in response to stressful life events, the development of aggressive behaviours, and post-traumatic stress disorder (PTSD).Genes202213230010.3390/genes13020300 35205345
     [Google Scholar]
/content/journals/cn/10.2174/1570159X22999240729103717
Loading
Vortioxetine versus SSRI/SNRI with Pregabalin Augmentation in Treatment-Resistant Burning Mouth Syndrome: A Prospective Clinical Trial
Curr. Neuropharmacol. 23, 800 (2025); https://doi.org/10.2174/1570159X22999240729103717
/content/journals/cn/10.2174/1570159X22999240729103717
/content/journals/cn/10.2174/1570159X22999240729103717
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): anxiety; Burning mouth syndrome; depression; pain; pregabalin; vortioxetine

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test